A brief introduction to Cantargia

CANFOUR clinical results, interview

Cantargia listed on Nasdaq Stockholm (Small Cap)

Two Nobel Prizes with utmost significance for Cantargia’s research

Cantargia is a biotechnology company specialising in dual-action antibody-based cancer treatments. CAN04, the company's patented antibody treatment, has a dual-action and fights cancer by activating the immune system and by blocking signals that lead to tumour growth. Treatment with CAN04 has the potential to become an important part of modern immunoncology.

Cantargia is since September 25, 2018 listed on Nasdaq Stockholm main market (Small Cap).

(R) Cantargia makes a directed share issue of approximately SEK 106 million for increased investments in the clinical development of CAN04

The board of directors of Cantargia AB (publ) has resolved, pursuant to the general meeting’s authorization, on a directed share issue of approximately SEK 106 million. T...

27/02/2019

(R) Cantargia publishes year end report for 2018

Cantargia AB’s (”Cantargia”) year end report for 2018 is now available on the company’s web page www.cantargia.com/en/investors/financial-reports.

25/01/2019

(R) Cantargia: first patient treated with antibody CAN04 in the phase IIa part of CANFOUR trial

Cantargia AB (publ) today announce that the first patient in the phase IIa part of the CANFOUR clinical trial has received CAN04 (nidanilimab) treatment in accordance wit...

10/12/2018

(R) Cantargia presents new positive preclinical data on antibody CAN04 at major antibody conference

Cantargia AB (publ) today announce that new preclinical data on the antibody CAN04 (nidanilimab) will be presented at the scientific conference Antibody Engineering and T...

07/12/2018

(R) Cantargia: Phase I safety evaluation part of CANFOUR trial of antibody CAN04 completed and phase IIa part being initiated

Cantargia AB (publ) today announces that all patients in the phase I part of the CANFOUR clinical trial have completed the formal safety evaluation phase of the trial. No...

15/11/2018

(R) Cantargia publishes interim report for third quarter of 2018

Cantargia AB’s interim report for the third quarter of 2018 is now available on the company’s web page www.cantargia.com/en/investors/financial-reports.

Show more press releases >>

Analysis

2019-03-08, Edison analysis of Cantargia